Investors
Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Karl Hård, Head of Investor Relations & Business Development
Phone: +46 733 011 944
Nicklas Westerholm, CEO
Phone: +46 733 542 06
April 14, 2026
Annual General Meeting
April 16, 2026
van Lanschot Kempen Life Sciences Conference (Amsterdam)
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: [email protected]
